GlassScriptPhysician profile
Eduardo Gomez
NPI 1851392369
$1,493.32
in general payments reported to CMS, 2019-2025
31 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $203 · 2021: $94.90 · 2022: $111 · 2023: $21.68 · 2024: $186 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $200.35 | 2025 | Reunion, Aequalis Flex Revive |
| Ermi LLC | $133.88 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $125.55 | 2019-2020 | |
| Heron Therapeutics, INC. | $120.95 | 2024 | Zynrelef |
| Mallinckrodt Enterprises LLC | $111.84 | 2019 | |
| Ferring Pharmaceuticals INC. | $84.00 | 2021-2022 | |
| Djo, LLC | $81.05 | 2019-2025 | Cmf |
| Si-Bone, INC. | $75.04 | 2019 | |
| Smith+Nephew, INC. | $71.43 | 2020 | |
| Amgen INC. | $43.42 | 2019-2020 | |
| Mml US, INC. | $42.18 | 2025 | Reactiv8 |
| Bioventus LLC | $41.37 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Pacira Therapeutics, INC. | $39.61 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $29.67 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $28.50 | 2025 | Exparel |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuros Medical, INC. | $27.53 | 2025 | Altius |
| Nevro Corp. | $26.47 | 2020 | |
| Fidia Pharma USA INC. | $25.73 | 2019-2021 | |
| Vericel Corporation | $23.77 | 2025 | Maci |
| Medtronic, INC. | $22.71 | 2024 | Inceptiv |
| Avanos Medical | $17.73 | 2024 | Grpro 2.1 |
| Mallinckrodt Hospital Products INC. | $17.71 | 2020 | |
| Carbofix Orthopedics INC | $15.18 | 2019 | |
| Pfizer INC. | $14.59 | 2021 | |
| Kci USA, INC. | $14.49 | 2022 | |
| Molnlycke Health Care US, LLC | $13.95 | 2022 | |
| Mvp Orthopedics INC | $13.61 | 2022 | |
| Coastal Medical Technologies LLC | $13.30 | 2023 | |
| Kerecis Limited | $9.33 | 2021 | |
| Heraeus Medical, LLC. | $8.38 | 2023 | Palacos |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,078,986.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.